Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.

Antibody response Children Infection SARS-CoV-2 Seroprevalence Vaccination

Journal

European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 14 11 2023
accepted: 19 12 2023
revised: 18 12 2023
pubmed: 4 1 2024
medline: 4 1 2024
entrez: 4 1 2024
Statut: ppublish

Résumé

Little information is available about the nature of the immune response in children after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination. The aim of this study is to define the seroprevalence and the features of the antibody response in children of Southern Switzerland during the different waves of Coronavirus Disease 2019 (COVID-19) pandemic. By analyzing 756 sera collected from children aged 0 to 16 years admitted to the Institute of Pediatrics of Southern Switzerland during the prepandemic period (before March 2020) and the first four pandemic waves (between March 2020 and June 2022), we investigated binding titers, cross-reactivity, and neutralizing properties of the serum antibodies against SARS-CoV-2 variants. Seroprevalence varied from 6% during the first wave to 14% and 17% during the second and third waves, respectively, peaking at 39% during the fourth wave. The 96 seropositive cases were mostly asymptomatic (42.7%) or showed mild (20.8%) to moderate (32.3%) symptoms. Moderate symptoms and close contact with COVID-19-positive individuals were associated with a higher infection risk (P < 0.001). The antibody response was mainly driven by IgG directed to the receptor-binding domain (RBD) of Wuhan-1 SARS-CoV-2 Spike (S). Children infected in the first three waves produced antibodies with up to 11-fold and 5.5-fold reduction in binding and neutralizing titers, respectively, against different SARS-CoV-2 variants, including Beta, Delta, and Omicron BA.1, BA.2, and BA.5. Such reductions were less pronounced in children infected during the fourth wave, who showed the highest frequency and titers of neutralizing antibodies against the same variants. Compared to infection, vaccination with a Wuhan-1-based messenger RNA (mRNA) vaccine induced higher and heterogenous levels of antibodies cross-reacting to the different SARS-CoV-2 variants analyzed.   Conclusions: Despite the high burden of COVID-19 in Southern Switzerland, we observed an initial low seroprevalence of SARS-CoV-2 in children, which increased in the later waves. The antibody response was poor in the first three waves and improved in the fourth wave, when children produced higher levels of neutralizing antibodies after vaccination or infection with Delta and/or Omicron variants. What is Known: • Children were marginally affected by the initial SARS-CoV-2 variants. • The number of infected and hospitalized children increased after the appearance of the Omicron variants. What is New: • Seroprevalence of SARS-CoV-2 in children of Southern Switzerland increased overtime. • Children produced higher levels of neutralizing antibodies after vaccination or infection with Delta and/or Omicron variants in the fourth wave compared to children infected in the first three waves.

Identifiants

pubmed: 38175262
doi: 10.1007/s00431-023-05400-7
pii: 10.1007/s00431-023-05400-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1425-1434

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Naeimi R, Sepidarkish M, Mollalo A, Parsa H, Mahjour S, Safarpour F, Almukhtar M, Mechaal A, Chemaitelly H, Sartip B, Marhoommirzabak E, Ardekani A, Hotez PJ, Gasser RB, Rostami A (2023) SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis. EClinicalMedicine 56:101786
doi: 10.1016/j.eclinm.2022.101786 pubmed: 36590788
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1211
doi: 10.1038/s41591-021-01377-8 pubmed: 34002089
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(281–292):e286
Dunay GA, Barroso M, Woidy M, Danecka MK, Engels G, Hermann K, Neumann FS et al (2023) Long-term antibody response to SARS-CoV-2 in children. J Clin Immunol 43:46–56
doi: 10.1007/s10875-022-01355-w pubmed: 36121535
Jacobsen EM, Fabricius D, Class M, Topfstedt F, Lorenzetti R, Janowska I, Schmidt F et al (2022) High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. Nat Commun 13:7315
doi: 10.1038/s41467-022-35055-1 pubmed: 36437276 pmcid: 9701757
Hitz P, Pagnamenta A, Pertusini L, Terrot T, Franzosi Y, Bassi J, Silacci-Fregni C, Gaia V, Martinetti G, Keller F, Berwert L, Ogna VF, Lavorato-Hadjeres S, Giunzioni D, D’Ermo A, Valnegri A, Ferrari P, Corti D, Ceschi A, Cippa P, Piccoli L, Giannini O (2023) Prevalence of SARS-CoV-2 infection and impact of vaccination in dialysis patients over two years of the pandemic. J Nephrol 36:2665–2667
doi: 10.1007/s40620-023-01754-1 pubmed: 37702913 pmcid: 10703959
Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, Giacchetto-Sasselli I, Terrot T, Silacci-Fregni C, Cameroni E, Jaconi S, Sprugasci N, Bartha I, Corti D, Uguccioni M, Lanzavecchia A, Garzoni C, Giannini O, Bernasconi E, Elzi L, Albanese E, Sallusto F, Ceschi A (2021) Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Reg Health Eur 1:100013
doi: 10.1016/j.lanepe.2020.100013 pubmed: 34173621
Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, Dang H et al (2023) Neutralization, effector function and immune imprinting of Omicron variants. Nature 621:592–601
doi: 10.1038/s41586-023-06487-6 pubmed: 37648855 pmcid: 10511321
Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C et al (2020) Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183(1024–1042):e1021
Marzi X, Bassi J, Silacci-Fregni C, Bartha I, Muoio F, Culap K, Sprugasci N et al (2023) Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. iScience 26:105726
doi: 10.1016/j.isci.2022.105726 pubmed: 36507220
Nathanielsz J, Toh ZQ, Do LAH, Mulholland K, Licciardi PV (2023) SARS-CoV-2 infection in children and implications for vaccination. Pediatr Res 93:1177–1187
doi: 10.1038/s41390-022-02254-x pubmed: 35970935
Nikolopoulou GB, Maltezou HC (2022) COVID-19 in children: where do we stand? Arch Med Res 53:1–8
doi: 10.1016/j.arcmed.2021.07.002 pubmed: 34311990
Medic S, Anastassopoulou C, Lozanov-Crvenkovic Z, Dragnic N, Petrovic V, Ristic M, Pustahija T, Tsakris A, Ioannidis JPA (2023) Incidence, risk, and severity of SARS-CoV-2 reinfections in children and adolescents between March 2020 and July 2022 in Serbia. JAMA Netw Open 6:e2255779
doi: 10.1001/jamanetworkopen.2022.55779 pubmed: 36780157 pmcid: 9926322
Beretta O, Casati Pagani S, Lazzaro M, Merlani G, Bouvier Gallacchi M (2021) Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months. Swiss Med Wkly 151:w30116
doi: 10.4414/SMW.2021.w30116 pubmed: 34964622
Ulyte A, Radtke T, Abela IA, Haile SR, Ammann P, Berger C, Trkola A, Fehr J, Puhan MA, Kriemler S (2021) Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona. Swiss Med Wkly 151:w30092
doi: 10.4414/SMW.2021.w30092 pubmed: 34797618
Comar M, Benvenuto S, Lazzerini M, Fedele G, Barbi E, Amaddeo A, Risso FM, Strajn T, Di Rocco P, Stefanelli P, Rezza G (2021) Prevalence of SARS-CoV-2 infection in Italian pediatric population: a regional seroepidemiological study. Ital J Pediatr 47:131
doi: 10.1186/s13052-021-01074-9 pubmed: 34090486 pmcid: 8179691
Filippatos F, Tatsi EB, Dellis C, Koukou DM, Papagiannopoulos C, Margeli A, Siahanidou T, Kanaka-Gantenbein C, Syriopoulou V, Michos A (2022) SARS-CoV-2 seroepidemiology in paediatric population during Delta and Omicron predominance. Epidemiol Infect 150:e177
doi: 10.1017/S0950268822001601 pubmed: 36345855
Brodin P (2022) SARS-CoV-2 infections in children: Understanding diverse outcomes. Immunity 55:201–209
doi: 10.1016/j.immuni.2022.01.014 pubmed: 35093190 pmcid: 8769938
Bullard J, Funk D, Dust K, Garnett L, Tran K, Bello A, Strong JE, Lee SJ, Waruk J, Hedley A, Alexander D, Van Caeseele P, Loeppky C, Poliquin G (2021) Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults. CMAJ 193:E601–E606
doi: 10.1503/cmaj.210263 pubmed: 33837039 pmcid: 8101972
Dioguardi M, Cazzolla AP, Arena C, Sovereto D, Caloro GA, Dioguardi A, Crincoli V, Laino L, Troiano G, Lo Muzio L (2021) Innate immunity in children and the role of ACE2 expression in SARS-CoV-2 infection. Pediatr Rep 13:363–382
doi: 10.3390/pediatric13030045 pubmed: 34287338 pmcid: 8293341
Seery V, Raiden S, Russo C, Borda M, Herrera L, Uranga M, Varese A et al (2022) Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: an observational cohort study. EBioMedicine 83:104230
doi: 10.1016/j.ebiom.2022.104230 pubmed: 35988465 pmcid: 9387350
Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, Borgert BA, Moreno CA, Solomon BD, Trimmer-Smith L, Etienne V, Rodriguez-Barraquer I, Lessler J, Salje H, Burke DS, Wesolowski A, Cummings DAT (2020) A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun 11:4704
doi: 10.1038/s41467-020-18450-4 pubmed: 32943637 pmcid: 7499300
Selva KJ, van de Sandt CE, Lemke MM, Lee CY, Shoffner SK, Chua BY, Davis SK et al (2021) Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat Commun 12:2037
doi: 10.1038/s41467-021-22236-7 pubmed: 33795692 pmcid: 8016934
Vilibic-Cavlek T, Stevanovic V, Ilic M, Barbic L, Capak K, Tabain I, Krleza JL, Ferenc T, Hruskar Z, Topic RZ, Kaliterna V, Antolovic-Pozgain A, Kucinar J, Koscak I, Mayer D, Sviben M, Antolasic L, Milasincic L, Bucic L, Ferencak I, Kaic B (2021) SARS-CoV-2 seroprevalence and neutralizing antibody response after the first and second COVID-19 pandemic wave in Croatia. Pathogens 10:774
doi: 10.3390/pathogens10060774 pubmed: 34203060 pmcid: 8235035
Bartsch YC, St Denis KJ, Kaplonek P, Kang J, Lam EC, Burns MD, Farkas EJ, Davis JP, Boribong BP, Edlow AG, Fasano A, Shreffler WG, Zavadska D, Johnson M, Goldblatt D, Balazs AB, Yonker LM, Alter G (2022) SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Sci Transl Med 14:eabn9237

Auteurs

Calogero Mazzara (C)

Institute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Jessica Bassi (J)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Chiara Silacci-Fregni (C)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Francesco Muoio (F)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Nadia Passini (N)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Davide Corti (D)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Giacomo D Simonetti (GD)

Institute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.

Federica Vanoni (F)

Institute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.

Lisa Kottanattu (L)

Institute of Pediatrics of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.

Luca Piccoli (L)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. lpiccoli@vir.bio.

Classifications MeSH